Semen astragali complanati- and rhizoma cibotii-enhanced bone formation in osteoporosis rats
详细信息 查看全文
- 作者：Meijie Liu (12)
Gary Guishan Xiao (13)
Peijing Rong (14)
Jiazi Dong (12)
Zhiguo Zhang (12)
Hongyan Zhao (12)
Jingru Teng (12)
Hongxia Zhao (12)
Jinghua Pan (12)
Yan Li (12)
Qinglin Zha (15)
Ying Zhang (12)
Dahong Ju (12) - 刊名：BMC Complementary and Alternative Medicine
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：13
- 期：1
- 全文大小：1762KB
- 参考文献：1. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis / Am J Med 1993, 94:646-50.
2. Chavassieux P, Seeman E, Delmas PD: Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. / Endocr Rev 2007, 28:151-64. CrossRef
3. Martin TJ, Sims NA: Osteoclast-derived activity in the coupling of bone formation to resorption. / Trends Mol Med 2005, 11:76-1. CrossRef
4. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J: Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. / Am J Pathol 2005, 166:467-76. CrossRef
5. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K: Are nonresorbing osteoclasts sources of bone anabolic activity? / J Bone Miner Res 2007, 22:487-94. CrossRef
6. Acconcia F, Barnes CJ, Kumar R: Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. / Endocrinology 2006, 147:1203-212. CrossRef
7. The Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal Woman. / JAMA 2002, 288:321-33. CrossRef
8. Liu M, Xiao GG, Rong P, Zhang Z, Dong J, Zhao H, Li H, Li Y, Pan J, Liu H, Wang W, Zha Q, Ju D: Long-term therapeutic effects of Radix Dipsaci, Pyrola Herb, and Cynomorium Songaricum on bone metabolism of ovariectomized rats. / BMC Complement Altern Med 2012. Accepted
9. Yasujima M, Abe K, Kanazawa M, Yoshida K, Kohzuki M, Sato M, Takeuchi K, Omata K, Tsunoda K, Kudo K: Effects of antihypertensive drugs on renal function and atrial natriuretic polypeptide in spontaneously hypertensive rats with renal ablation. / Tohoku J Exp Med 1989, 158:85-4. CrossRef
10. Dunlap JE: Preventing broken appointments. / Dent Econ 1976, 66:44-. 47
11. Tyrovola JB, Spyropoulos MN, Makou M, Perrea D: Root resorption and the OPG/RANKL/RANK system: a mini review. / J Oral Sci 2008, 50:367-76. CrossRef
12. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. / JAMA 2004, 292:490-95. CrossRef
13. Van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewe RB, Dijkmans BA, Lems WF: Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. / Ann Rheum Dis 2010, 69:1623-628. CrossRef
14. Liu ZG, Zhang R, Li C, Ma X, Liu L, Wang JP, Mei QB: The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. / J Ethnopharmacol 2009, 123:74-1. CrossRef
15. Seeman E, Delmas PD: Bone quality--the material and structural basis of bone strength and fragility. / N Engl J Med 2006, 354:2250-261. CrossRef
16. Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. / Endocr Rev 2008, 29:155-92. CrossRef
17. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A: Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. / Gene 1997, 204:35-6. CrossRef
18. Woo KM, Choi Y, Ko SH, Ko JS, Oh KO, Kim KK: Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. / Exp Mol Med 2002, 34:347-52. CrossRef
19. Kondo T, Kitazawa R, Maeda S, Kitazawa S: 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. / J Bone Miner Res 2004, 19:1411-419. CrossRef
20. Kwan TS, Padrines M, Theoleyre S, Heymann D, Fortun Y: IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. / Cytokine Growth Factor Rev 2004, 15:49-0. CrossRef
21. Khosla S: Minireview: the OPG/RANKL/RANK system. / Endocrinology 2001, 142:5050-055. CrossRef
22. Hofbauer LC, Heufelder AE: Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases. / Dtsch Med Wochenschr 2001, 126:145-50. CrossRef
23. Gravallese EM, Goldring SR: Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. / Arthritis Rheum 2000, 43:2143-151. CrossRef
24. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. / Genes Dev 1998, 12:1260-268. CrossRef
25. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL: The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. / J Cell Biol 1999, 145:527-38. CrossRef
26. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N: Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. / Bone 1998, 23:495-98. CrossRef
27. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/141/prepub - 作者单位：Meijie Liu (12)
Gary Guishan Xiao (13)
Peijing Rong (14)
Jiazi Dong (12)
Zhiguo Zhang (12)
Hongyan Zhao (12)
Jingru Teng (12)
Hongxia Zhao (12)
Jinghua Pan (12)
Yan Li (12)
Qinglin Zha (15)
Ying Zhang (12)
Dahong Ju (12)
12. Institute of Basic Theory, China Academy of Chinese Medical Sciences, South Small Street 16, Dongzhimennei, Dongcheng District, Beijing, 100700, China
13. Functional Genomics & Proteomics Laboratory, Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE, 68131, USA
14. Institute of Acupuncture Moxibustion, China Academy of Chinese Medical Sciences, South Small Street 16, Dongzhimennei, Dongcheng District, Beijing, 100700, China
15. Jiangxi College of Traditional Chinese Medicine, Yunwan Road 18, Wanli District, Nanchang City, Jiangxi, 330004, China
文摘
Background Growing evidence shows that herb medicines have some anti-osteoporotic effects, the mechanism underlying is unknown. This study aims to investigate the therapeutic effect of Chinese herb supplements on rats that had osteoporosis-like symptom induced by ovariectomy (OVX). Methods OVX or sham operations were performed on virgin Wistar rats at three-month old, which were randomly divided into eight groups: sham (sham); OVX control group (OVX); OVX rats with treatments [either diethylstilbestrol (DES) or Semen Astragali Complanati decoction (SACD) or Rhizoma Cibotii decoction (RCD) or Herba Cistanches decoction (HCD) or Semen Allii Tuberosi decoction (SATD)]. Non-surgical rats were served as a normal control (NC). The treatments began 4 weeks after surgery, and lasted for 12 weeks. Bone mass and its turnover were analyzed by histomorphometry. Levels of protein and mRNA of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in osteoblasts (OB) and bone marrow stromal cells (bMSC) were evaluated by immunohistochemistry and in situ hybridization. Results Compared to OVX control, TBV% in both SACD and RCD groups was increased significantly, while TRS%, TFS%, MAR, and mAR were decreased remarkably in the SACD group, only TRS% decreased dramatically in the RCD group. No significant changes in bone formation were observed in either HCD or SATD groups. OPG levels in both protein and mRNA were reduced consistantly in OB and bMSC from OVX control rats, in contrast, RANKL levels in both protein and mRNA were increased significantly. These effects were substantially reversed by treatments with either DES or SACD or RCD. No significant changes in both OPG and RANKL expression were observed in OB and bMSC from OVX rats treated with SATD and HCD. Conclusions Our study showed that SACD and RCD increased bone formation by stimulating OPG expression and downregulating RANKL expression in OB and bMSC. This suggests that SACD and RCD may be developed as alternative anti-osteoporotic agents for therapy of postmenopausal osteoporosis.